Barbara Harlin Bispham - 15 Dec 2025 Form 4 Insider Report for CRESCENT BIOPHARMA, INC. (GLYC)

Role
General Counsel and Corporate Secretary.
Signature
/s/ Barbara Bispham
Issuer symbol
GLYC
Transactions as of
15 Dec 2025
Net transactions value
$0
Form type
4
Filing time
17 Dec 2025, 16:35:36 UTC
Previous filing
30 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bispham Barbara Harlin General Counsel and Corporate Secretary. C/O CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM /s/ Barbara Bispham 17 Dec 2025 0002075230

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBIO Ordinary Shares Award +12,422 12,422 15 Dec 2025 Direct F1
transaction CBIO Ordinary Shares Award +6,000 +48% 18,422 15 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBIO Stock Option (Right to Buy) Award $0 +72,185 $0.000000 72,185 15 Dec 2025 Ordinary Shares 72,185 $13.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.
F2 This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

Remarks:

General Counsel and Corporate Secretary.